001 Urinary and Sexual Function in 411 Obese Hypogonadal Men with and without Testosterone Therapy: Real-life Evidence from a 10-registry Study in a Urological Office

Abstract

Obesity negatively affects urinary and erectile function. We investigated effects of long-term testosterone therapy (TTh) from a registry including an untreated hypogonadal control group. 267 obese men with testosterone ≤350 ng/dL and symptoms of hypogonadism received testosterone undecanoate 1000 mg every 3 months following an initial 6-week interval for up to 10 years. 174 hypogonadal men opted against testosterone therapy (TTh). Urinary function was assessed subjectively by IPSS and objectively by ultrasound-measured post-voiding residual bladder volume (RBV), erectile function by IIEF-EF. Differences between groups were estimated and adjusted for age and metabolic syndrome parameters to account for baseline differences between groups. Mean age: 61±6 years (T-group: 60±6, CTRL: 64±5). IPSS decreased from 7.4±3.8 to 1.9±0.7 (p<0.0001) at 10 years in the T-group and from 4.9±1.8 to 4.3±3.7 (NS) in CTRL, estimated adjusted between-group difference: -4.4 (p<0.0001). RBV decreased from 55±22 to 10±2 mL (p<0.0001) at 10 years in the T-group and increased from 52±15 to 58±23 mL (p<0.05) in CTRL, estimated adjusted between-group difference: -56 mL (p<0.0001). IIEF-EF increased from 19.1±5.2 to 27.1±1.6 at 10 years in the T-group and decreased from 19.4±3.6 to 9±2 in CTRL, estimated adjusted between-group difference: +19.2 (p<0.0001 for all).